November 24, 2021 Regulatory InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021 Read more
November 16, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada Read more
November 9, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in the US Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021 Read more
August 24, 2021 Regulatory InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod Read more
June 3, 2021 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 31, 2021 Regulatory InDex Pharmaceuticals will initiate patient recruitment for the Phase III study CONCLUDE after the summer Read more
May 5, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021 Read more
May 4, 2021 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 23, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020 Read more
January 21, 2021 Regulatory InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue Read more
January 14, 2021 Regulatory The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533 Read more
January 12, 2021 Regulatory Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more